Treximet Articles
Pozen sells future royalty rights to Treximet for $75 million
28 November 2011
Pozen cuts loss 53%, attracts Zacks interest
6 May 2009
Pozen shares drop 28% on Treximet challenge
27 October 2008
$20M GSK milestone for Pozen
5 May 2008
GSK's Treximet receives FDA approval
21 April 2008
Showing 1-6 of 6 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
